Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Melanoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Newly Diagnosed Glioblastoma 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Lymphoma, Large B-Cell, Diffuse 1Locally Advanced or Metastatic Solid Tumors 1Glioma 1Carcinoma, Merkel Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 180Cisplatin 44Paclitaxel 41Carboplatin 41lenvatinib 31Docetaxel 22Pemetrexed 20Fluorouracil 19Capecitabine 16Gemcitabine 15Saline Solution 13Oxaliplatin 13Albumin-Bound Paclitaxel 10epacadostat 9130-nm albumin-bound paclitaxel 9Leucovorin 8Cetuximab 8olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6belzutifan 5Dexamethasone 5enzalutamide 4trifluridine tipiracil drug combination 3regorafenib 3patritumab deruxtecan 3enfortumab vedotin 3durvalumab 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Parkinson Disease 4, Autosomal Dominant Lewy Body × efineptakin alfa × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡